Emergency Preparedness & Response
- Specific Hazards
- Bioterrorism
- A–Z
- Anthrax
- What You Need To Know
- Mail Handlers
- Questions & Answers
- Additional Fact Sheets & Overviews
- Cutaneous Anthrax
- Diagnosis
- Environment
- Exposure Management
- Infection Control
- Lab Testing
- Images
- Preparation & Planning
- References
- Surveillance & Investigation
- Training & Education
- Treatment
- Vaccination
- Work Safety
- Arenaviruses
- Botulism
- Brucella
- Cholera
- Ebola virus
- E. coli
- Food safety threats
- Glanders
- Lassa fever
- Marburg virus
- Melioidosis
- Plague
- Q fever
- Salmonella
- Shigella
- Smallpox
- Smallpox Basics
- Vaccine Basics
- Clinicians
- Vaccination Q & A (for professionals)
- Health Officials
- People Selected for Response Teams
- Diagnosis/
Evaluation - Lab Testing
- Infection Control
- Surveillance & Investigation
- Preparation & Planning
- Response
- Vaccination
- Images
- Medical Management
- Training & Education
- References
- Tularemia
- Typhoid fever
- Viral hemorrhagic fevers
- Anthrax
- List by Category
- Fact Sheets
- Case Definitions
- Training
- Surveillance
- Preparation & Planning
- First Responders
- Lab Info
- A–Z
- Chemical
- A–Z
- Abrin
- Adamsite
- Ammonia
- Arsenic
- Arsine
- Barium
- Benzene
- Brevetoxin
- Bromine
- BZ
- Carbon monoxide
- Chlorine
- Chromium
- Colchicine
- Cyanide
- Digitalis
- Ethylene glycol
- Hydrazine
- Hydrofluoric acid
- Hydrogen chloride
- Lewisite
- Melamine
- Mercury
- Methyl bromide
- Methyl isocyanate
- Nicotine
- Nitrogen mustard
- Opioids
- Organic solvents
- Osmium tetroxide
- Paraquat
- Phosgene
- Phosgene oxime
- Phosphine
- Phosphorus
- Ricin
- Sarin
- Saxitoxin
- Selenium
- Sodium azide
- Sodium monofluoroacetate
- Soman
- Strychnine
- Sulfur mustard
- Sulfuryl Fluoride
- Super Warfarin
- Tabun
- Tetrodotoxin
- Thallium
- Trichothecene
- Unidentified Chemical
- VX
- List by Category
- Chemical-Specific Fact Sheets
- Toxicology FAQs
- Case Definitions
- Toxic Syndrome Descriptions
- Toxicological Profiles
- Training
- First Responders
- Medical Management
- Emergency Response Cards
- Lab Info
- Surveillance
- Preparation & Planning
- A–Z
- Gulf Oil Spill 2010
- Radiation
- Mass Casualties
- Natural Disasters & Severe Weather
- Recent Outbreaks & Incidents
- Bioterrorism
- Preparedness for All Hazards
- Children
- Clinician Resources
- About COCA
- COCA Partner Organizations
- COCA Conference Calls
- Conference Calls - 2013
- Conference Calls - 2012
- Conference Calls - 2011
- Conference Calls - 2010
- June 3, 2010
- June 9, 2010
- June 22, 2010
- July 8, 2010
- July 27, 2010
- August 3, 2010
- August 17, 2010
- August 30, 2010
- September 2, 2010
- September 16, 2010
- September 21, 2010
- September 22, 2010
- October 1, 2010
- November 2, 2010
- November 9, 2010
- November 23, 2010
- December 2, 2010
- December 7, 2010
- December 14, 2010
- December 15, 2010
- Continuing Education Credit for COCA Calls
- Updates & Reminders
- Reminders - 2012
- Reminders - 2011
- Reminders - 2010
- Updates - 2013
- Updates - 2012
- January 3, 2012
- January 17, 2012
- January 30, 2012
- February 13, 2012
- February 27, 2012
- March 12, 2012
- March 26, 2012
- April 9, 2012
- April 23, 2012
- May 7, 2012
- May 21, 2012
- June 4, 2012
- June 18, 2012
- July 2, 2012
- July 16, 2012
- July 30, 2012
- August 13, 2012
- August 27, 2012
- September 10, 2012
- September 24, 2012
- October 8, 2012
- October 22, 2012
- November 5, 2012
- November 19, 2012
- December 3, 2012
- Updates - 2011
- January 3, 2011
- January 18, 2011
- January 31, 2011
- February 14, 2011
- February 28, 2011
- March 14, 2011
- March 21, 2011
- April 4, 2011
- April 11, 2011
- April 25, 2011
- May 9, 2011
- May 23, 2011
- June 6, 2011
- June 20, 2011
- July 5, 2011
- July 18, 2011
- August 1, 2011
- August 15, 2011
- August 29, 2011
- September 12, 2011
- September 26, 2011
- October 11, 2011
- November 7, 2011
- November 21, 2011
- December 5, 2011
- December 19, 2011
- Updates - 2010
- Join the COCA Mailing List
- Conference & Training Opportunities
- Emergency Preparedness and Response Training Resources
- Communicating in the First Hours
- Coping with a Disaster
- Crisis & Emergency Risk Communication (CERC)
- Health Alert Network (HAN)
- HAN Jurisdictions
- HAN Message Types
- Sign-Up for HAN Updates
- HAN Archive
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- HAN00219
- HAN00218
- HAN00217
- HAN00216
- HAN00215
- HAN00214
- HAN00213
- HAN00212
- HAN00211
- HAN00210
- HAN00209
- HAN00208
- HAN00207
- HAN00206
- HAN00205
- HAN00204
- HAN00203
- HAN00202
- HAN00201
- HAN00200
- HAN00199
- HAN00198
- HAN00197
- HAN00196
- HAN00195
- HAN00194
- HAN00193
- HAN00192
- HAN00191
- HAN00190
- HAN00189
- HAN00188
- HAN00187
- HAN00186
- HAN00185
- HAN00184
- HAN00183
- HAN00182
- HAN00181
- 2003
- HAN00180
- HAN00179
- HAN00178
- HAN00177
- HAN00176
- HAN00175
- HAN00174
- HAN00173
- HAN00172
- HAN00171
- HAN00170
- HAN00169
- HAN00168
- HAN00167
- HAN00166
- HAN00165
- HAN00164
- HAN00163
- HAN00162
- HAN00161
- HAN00160
- HAN00159
- HAN00158
- HAN00157
- HAN00156
- HAN00155
- HAN00154
- HAN00153
- HAN00152
- HAN00151
- HAN00150
- HAN00149
- HAN00148
- HAN00147
- HAN00146
- HAN00145
- HAN00144
- HAN00143
- HAN00142
- HAN00141
- HAN00140
- HAN00139
- HAN00138
- HAN00137
- HAN00136
- HAN00135
- HAN00134
- HAN00133
- HAN00132
- HAN00131
- HAN00130
- HAN00129
- HAN00128
- HAN00127
- HAN00126
- HAN00125
- HAN00124
- HAN00123
- HAN00122
- HAN00121
- HAN00120
- HAN00119
- HAN00118
- HAN00117
- HAN00116
- HAN00115
- HAN00114
- HAN00113
- HAN00112
- HAN00111
- HAN00110
- HAN00109
- HAN00108
- 2002
- HAN00107
- HAN00106
- HAN00105
- HAN00104
- HAN00103
- HAN00102
- HAN00101
- HAN00100
- HAN00099
- HAN00098
- HAN00097
- HAN00096
- HAN00095
- HAN00094
- HAN00093
- HAN00092
- HAN00091
- HAN00090
- HAN00089
- HAN00088
- HAN00087
- HAN00086
- HAN00085
- HAN00084
- HAN00083
- HAN00082
- HAN00081
- HAN00080
- HAN00079
- HAN00078
- HAN00077
- HAN00076
- HAN00075
- HAN00074
- HAN00073
- HAN00072
- HAN00071
- HAN00070
- HAN00069
- HAN00068
- HAN00067
- 2001
- HAN00066
- HAN00065
- HAN00064
- HAN00063
- HAN00062
- HAN00061
- HAN00060
- HAN00059
- HAN00058
- HAN00057
- HAN00056
- HAN00055
- HAN00054
- HAN00053
- HAN00052
- HAN00051
- HAN00050
- HAN00049
- HAN00048
- HAN00047
- HAN00046
- HAN00045
- HAN00044
- HAN00043
- HAN00042
- HAN00041
- HAN00040
- HAN00039
- HAN00038
- HAN00037
- HAN00036
- HAN00035
- HAN00034
- HAN00033
- HAN00032
- HAN00031
- HAN00030
- HAN00029
- HAN00028
- HAN00027
- HAN00025
- HAN00024
- HAN00023
- HAN00022
- HAN00021
- HAN00020
- HAN00019
- HAN00018
- HAN00017
- HAN00016
- HAN00015
- HAN00014
- HAN00013
- HAN00012
- HAN00011
- HAN00010
- HAN00009
- HAN00008
- HAN00007
- HAN00006
- HAN00005
- HAN00004
- HAN00003
- HAN00002
- HAN00001
- Lab Info
- Laboratory Response Network (LRN)
- Preparation & Planning
- Related Links
- Risk Communicator
- Issue 3
- Issue 2
- Priceless Collaboration for Hurricane Preparedness
- Talking to WHO's John Rainford - New WHO Guidelines
- Emergency Communication Challenges in Hurricane Katrina Response
- Hurricane Readiness in High-Risk Areas: Survey Results
- Elements of a Successful Exercise: Functional vs Tabletop and Beyond
- Collaboration & Communication During Emergency Response
- Public Health Observances
- Calendar of Training Opportunities
- Contributors
- Issue 1
- Introduction to the Risk Communicator
- Social Media & Emergency Communication
- Messaging Is Matter of Trust
- Program Spotlight: Frontlines of the CA Wildfires
- Research Summaries: Summaries of Work from Deborah Glik and Craig Lefebvre
- Risk Communication Opportunities During National Observances
- Upcoming Conferences, Training, and Workshops of Interest to Risk Communicators
- Contributors
- About the Newsletter
- SNAPS
- Social Media
- Surveillance
- Training & Education
- What CDC Is Doing
- What You Can Do
- Blog: Public Health Matters
- What's New
- A - Z Index
SMALLPOX SUPPLEMENTAL FACT SHEET
Investigational Vistide® (Cidofovir) Information
The smallpox vaccine is made from a live virus related to smallpox called vaccinia. The vaccine stimulates the immune system to react against the vaccinia virus, and develop immunity to it. Immunity to vaccinia also provides immunity to smallpox. For most people, live virus vaccines are safe and effective. Some people, however, are at greater risk for serious side effects from the smallpox vaccine.
Vistide (cidofovir), a drug licensed to treat serious viral infections of the eye in HIV-infected people, may help people who have certain serious reactions to the smallpox vaccine. If you develop a serious reaction to the smallpox vaccine, and VIG (another medicine used to treat bad reactions to the smallpox vaccine) is not available or is not working, you may be offered cidofovir. While this drug has not been used to treat patients with bad reactions to smallpox vaccine, early results from laboratory studies suggest that cidofovir may work against the vaccinia virus. Use of cidofovir would be administered under an Investigational New Drug (IND) protocol.
Cidofovir Information:
- VistideĀ® (Cidofovir) is licensed to treat cytomegalvirus (CMV) retinitis (a serious eye infection) in HIV-infected people. It is not licensed to treat the problems caused by smallpox vaccine so it can only be used 'off-label' (prescribed by a physician to treat a condition for which it has not been specifically approved) or through a special protocol called an Investigational New Drug (IND) protocol.
- Use of cidofovir to treat smallpox vaccine reactions should be evaluated and monitored by experts at the National Institutes of Health and the Centers for Disease Control and Prevention.
- Cidofovir might be used to treat individuals who have developed generalized vaccinia, eczema vaccinatum, or progressive vaccinia after receiving the smallpox vaccine.
How is cidofovir administered?
Cidofovir is injected through a needle in the vein. Fluids will be given through the vein and another medication (probenecid) given by mouth both before and after cidofovir. These may help decrease the side effects of cidofovir.
Side Effects:
- Kidney problems that can lead to kidney failure.
- Low white blood cells.
- Pressure in the eye.
- Swelling and tenderness of the eye.
- Build up of acid in the body that can result in liver problems and inflammation of the pancreas that can result in death.
- Other problems include fever, infection, pneumonia, shortness of breath and nausea with vomiting.
- Cidofovir can cause headache, weakness, rash, hair loss, diarrhea, pain, lowered number of red blood cells, loss of appetite, chills, coughing, and infections in the mouth.
- Share
- Add this to...
- Favorites
- Del.icio.us
- Digg
- Google Bookmarks
- Technorati
- Yahoo MyWeb
- Updates
- Subscribe
- Listen
- Page last reviewed March 10, 2009
- Page last updated March 10, 2009
- Content source: Division of Bioterrorism Preparedness and Response (DBPR), National Center for Preparedness, Detection, and Control of Infectious Diseases (NCPDCID), Office of Infectious Diseases
- Email page
- Print page
- Bookmark and share
- Add this to...
- Favorites
- Del.icio.us
- Digg
- Google Bookmarks
- Technorati
- Yahoo MyWeb
View page in
Get email updates
To receive email updates about this page, enter your email address:
Contact Us:
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348 - Contact CDC-INFO


